United Therapeutics
Stock Forecast, Prediction & Price Target
United Therapeutics (UTHR) stock Price Target by analysts
$412.5
Potential upside: 31.69%
United Therapeutics price prediction
What is United Therapeutics stock analysts` prediction?
United Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for United Therapeutics in the last 3 months, the avarage price target is $412.5, with a high forecast of $NaN. The average price target represents a 31.69% change from the last price of $313.22.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
United Therapeutics stock Price Target by analysts
Full breakdown of analysts given United Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Andrew Fein H.C. Wainwright | 0% 0/1 | 11 months ago | $425 35.68% upside | $361.4 | StreetInsider | Previous targets (0) |
Jasper Hellweg Argus Research | 0% 0/1 | 11 months ago | $400 27.70% upside | $362.36 | TheFly | Previous targets (0) |
Eun Yang Jefferies | 0% 0/1 | about 1 year ago | $432 37.92% upside | $353 | StreetInsider | Previous targets (0) |
Hartaj Singh Oppenheimer | 0% 0/2 | about 1 year ago | $575 83.57% upside | $362.45 | StreetInsider | Previous targets (1) |
Ashwani Verma UBS | 0% 0/1 | about 1 year ago | $370 18.12% upside | $317.18 | StreetInsider | Previous targets (0) |
Tiago Fauth Wells Fargo | 0% 0/1 | over 1 year ago | $350 11.74% upside | $275.76 | TheFly | Previous targets (0) |
Hartaj Singh Oppenheimer | 0% 0/2 | over 1 year ago | $400 27.70% upside | $255.14 | TheFly | Previous targets (1) |
Chris Shibutani Goldman Sachs | 100% 1/1 | over 1 year ago | $215 -31.35% downside | $214.74 | Benzinga | Previous targets (0) |
Unknown Argus Research | N/A | over 2 years ago | $300 -4.22% downside | $263.41 | Benzinga | N/A |
Unknown UBS | N/A | almost 3 years ago | $320 2.16% upside | $273.72 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $330 5.35% upside | $276.07 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | almost 3 years ago | $230 -26.56% downside | $278.55 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | over 3 years ago | $255 -18.58% downside | $210.14 | Benzinga | N/A |
Unknown Credit Suisse | N/A | over 3 years ago | $247 -21.14% downside | $210.14 | Benzinga | N/A |
Unknown Jefferies | N/A | over 3 years ago | $245 -21.78% downside | $217.14 | Benzinga | N/A |
Unknown J.P. Morgan | N/A | over 3 years ago | $238 -24.01% downside | $218 | Benzinga | N/A |
Unknown J.P. Morgan | N/A | over 3 years ago | $223 -28.80% downside | $184.24 | Benzinga | N/A |
Tiago Fauth Credit Suisse | 100% 1/1 | over 4 years ago | $205 -34.55% downside | $198.14 | StreetInsider | Previous targets (0) |
United Therapeutics Financial Estimates
United Therapeutics Revenue Estimates
United Therapeutics EBITDA Estimates
United Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.68B N/A | $1.93B 14.87% | $2.32B 20.20% | Avg: $2.96B Low: $2.72B High: $3.29B avg. 27.57% | Avg: $3.16B Low: $2.92B High: $3.46B avg. 6.46% | Avg: $3.29B Low: $3.04B High: $3.61B avg. 4.33% | Avg: $3.41B Low: $3.15B High: $3.73B avg. 3.48% |
Net Income
% change YoY
| $475.8M N/A | $727.3M 52.85% | $984.8M 35.40% | Avg: $1.29B Low: $1.07B High: $1.87B avg. 31.78% | Avg: $1.31B Low: $840.42M High: $1.56B avg. 1.16% | Avg: $1.47B Low: $1.33B High: $1.65B avg. 12.50% | Avg: $1.70B Low: $1.53B High: $1.91B avg. 15.64% |
EBITDA
% change YoY
| $614.8M N/A | $984.7M 60.16% | $1.38B 40.83% | Avg: $1.09B Low: $1.00B High: $1.21B avg. -21.27% | Avg: $1.16B Low: $1.07B High: $1.27B avg. 6.46% | Avg: $1.21B Low: $1.12B High: $1.32B avg. 4.33% | Avg: $1.25B Low: $1.16B High: $1.37B avg. 3.48% |
EPS
% change YoY
| $10.6 N/A | $15.98 50.75% | $21.04 31.66% | Avg: $26.94 Low: $21.67 High: $37.65 avg. 28.06% | Avg: $26.93 Low: $16.91 High: $31.41 avg. -0.05% | Avg: $29.72 Low: $26.79 High: $33.37 avg. 10.35% | Avg: $34.37 Low: $30.99 High: $38.59 avg. 15.64% |
Operating Expenses
% change YoY
| $1.00B N/A | $809.9M -19.58% | $885.1M 9.28% | Avg: $743.17M Low: $683.20M High: $824.01M avg. -16.03% | Avg: $791.22M Low: $731.29M High: $866.03M avg. 6.46% | Avg: $825.53M Low: $763.01M High: $903.58M avg. 4.33% | Avg: $854.30M Low: $789.59M High: $935.07M avg. 3.48% |
FAQ
What is United Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 15.27% in 2025-2028.
We have gathered data from 12 analysts. Their low estimate is 1.07B, average is 1.29B and high is 1.87B.
What is United Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 10.46% in 2025-2028.
We have gathered data from 11 analysts. Their low revenue estimate is $2.72B, average is $2.96B and high is $3.29B.
What is United Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 13.50% in 2025-2028.
We have gathered data from 12 analysts. Their low earnings per share estimate is $21.67, average is $26.94 and high is $37.65.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering United Therapeutics stock. The most successful analyst is Andrew Fein.